Weight loss with FDA-approved GLP-1 medications can reduce measured lean mass alongside fat mass. In the SURMOUNT-1 body-composition substudy, about 74% of weight lost with tirzepatide came from fat mass and 26% from lean mass after 72 weeks. Participants receiving placebo and lifestyle counseling lost a similar proportion of weight from fat mass. The researchers described tirzepatide’s proportional lean-mass loss as similar to that seen with other weight-loss methods.
Lean mass on a DXA scan includes muscle, but it also includes water, organs, and other tissue. The SURMOUNT-1 figures therefore do not mean participants lost 26% of their muscle, and the scans do not establish whether they became weaker. An exploratory STEP 1 analysis of semaglutide also reported reductions in fat and lean mass. Separate trials cannot show which medication better preserves muscle or strength.
For patients considering medical GLP-1 weight-loss care, these findings describe approved products given at trial doses with lifestyle counseling, not a guaranteed individual outcome. FDA-approved products provide standardized formulations and labeled dosing. A licensed provider may prescribe a compounded preparation for a documented, patient-specific need that an approved product does not meet, but compounded medications are not FDA-approved. The approved-product trial results cannot be assumed to apply to compounded semaglutide or tirzepatide.
A DXA scan measures lean mass, not muscle strength. Its lean-mass category includes skeletal muscle, organs, water, and connective tissue. A lower reading therefore cannot show how much muscle you lost or whether you have become weaker.
The STEP 1 semaglutide analysis and SURMOUNT-1 tirzepatide analysis reported changes in DXA-measured body composition. Neither analysis reported grip strength, gait speed, or similar measures of physical function alongside the scans. Their results show that lean mass changed, but they do not establish whether participants found it harder to climb stairs, carry groceries, or perform their usual activities.
A DXA result can help you and your clinician discuss body-composition changes. Tracking what you can do in daily life adds information the scan cannot provide.
A scale can show weight loss, but your usual activities can reveal whether your strength is changing. Notice whether carrying the same grocery bags, climbing familiar stairs, or opening a jar feels harder than it used to. If you exercise, compare how a familiar movement feels under similar conditions rather than judging one difficult workout.
Look for a pattern, not a single bad day. Poor sleep, illness, and eating too little can temporarily affect performance. You can note what changed, when you noticed it, and whether it continues. These observations help you describe a concern to your provider, but they do not diagnose muscle loss or replace a clinical assessment.
Tell your clinician if weakness persists, your usual activities keep getting harder, or fatigue seems out of proportion to your weight loss. Your clinician can review your symptoms, food intake, activity, and other possible causes before recommending any changes. Do not change your medication dose or frequency on your own.
Adequate protein gives your body material to maintain muscle during weight loss, while resistance exercise gives muscles a reason to keep working. Appetite suppression can make it harder to eat enough overall. A joint clinical advisory recommends nutritional assessment, adequate protein, and strength training during GLP-1 treatment. The advisory offers clinical guidance, not proof that a particular diet or exercise routine prevents lean-mass loss.
Ask your clinician or dietitian to help you plan meals around your appetite, health conditions, and activity. If nausea or reduced appetite regularly keeps you from eating enough, Optima Tyler’s GLP-1 nausea and food guide offers food-choice ideas to discuss with them. Protein needs vary, so a generic target may not suit you, particularly if you have kidney disease or other nutritional concerns.
Resistance exercise can help you maintain strength because working muscles respond to repeated effort. Your clinician can help you choose an appropriate starting point if you have joint pain, limited mobility, or little training experience. As you review your weight-loss results timeline, pay attention to whether familiar tasks and exercises feel harder. The scale cannot tell you whether your strength has changed.
FDA-approved semaglutide and tirzepatide provide standardized formulations and labeled dosing. Compounding offers a patient-specific pathway when a licensed provider documents why a change to an approved product makes a clinically significant difference for an individual patient. A licensed pharmacy then prepares the medication for that patient’s prescription.
The body-composition trials discussed above studied FDA-approved products. They cannot establish how much lean mass someone will lose while taking a compounded preparation or whether that person’s strength will change. Compounded medications are not FDA-approved, and they do not undergo FDA premarket review for safety, effectiveness, or quality. Individualized treatment may meet a documented medical need, but it does not establish equivalent or better outcomes.
Follow your prescription and provider’s instructions for dose and frequency. Do not change either on your own. If you are switching between a compounded medication and an approved product, ask your clinician to manage the transition.
FDA-approved GLP-1 medications have standardized formulations and labeled dosing. Optima Tyler’s medical weight-loss care offers a different, patient-specific pathway when a licensed provider documents that an approved product does not adequately meet your medical needs. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not review them before marketing for safety, effectiveness, or quality.
Optima’s evaluation and follow-up give you a place to discuss strength as your weight changes. Tell your clinician if carrying groceries, climbing stairs, or completing your usual exercise feels harder. Follow-up visits also let you discuss whether you are eating enough and what resistance training suits your health and abilities. Trial results for approved GLP-1 products cannot establish what will happen with a compounded preparation.
Optima sources patient-specific prescriptions from licensed pharmacy partners. Its compounded medication comes in a vial for injection under the skin with an insulin syringe, rather than a branded prefilled pen. Optima’s injection-training video demonstrates the vial-and-syringe method, and its general GLP-1 guide covers the broader treatment process. Follow your prescription and provider instructions, and do not change your dose or injection frequency on your own.
Does tirzepatide cause more muscle loss than semaglutide? The tirzepatide and semaglutide body-composition analyses came from separate trials. Their DXA scans measured lean mass, which includes more than skeletal muscle. The studies do not establish which medication causes more muscle loss or greater loss of strength.
Can resistance training fully prevent lean-mass loss? No study establishes that resistance training prevents all lean-mass loss during semaglutide or tirzepatide treatment. A joint clinical advisory recommends strength training and adequate protein to help preserve lean mass. Ask your clinician what activity and nutrition plan fits your health and current abilities.
Is muscle loss reversible after stopping a GLP-1 medication? The body-composition trials do not establish whether an individual's lost skeletal muscle returns after treatment stops. If you have noticed persistent weakness, ask your clinician to assess your strength, activity, and nutrition rather than assuming a change on the scale reflects muscle recovery.
Should I get a DXA scan? A DXA scan can estimate changes in lean mass, but it cannot tell you whether your grip, walking, or ability to carry groceries has declined. Discuss a scan with your clinician if its result would help guide your care.
Does compounded medication carry the same muscle-loss risk as brand-name drugs? FDA-approved products have standardized formulations and labeled dosing. Compounding can provide patient-specific customization when a licensed provider documents that an approved product does not meet an individual's medical needs. Compounded medications are not FDA-approved, so approved-product trial outcomes cannot establish their muscle-loss risk. Follow your prescription and ask your provider about any strength concerns. Do not change your dose or frequency on your own.
Preserving strength during GLP-1 treatment takes ongoing review with your provider, especially if everyday tasks start to feel harder. Tell your provider about changes in your usual activities rather than judging your progress by weight alone. At follow-up, a licensed clinician can consider those changes alongside your nutrition and treatment response, then discuss whether your care plan needs to change. If you’re receiving care through Optima Tyler, you can schedule a follow-up evaluation to discuss concerns about your strength and function.